Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.

Yuankai Shi,Xingsheng Hu,Shucai Zhang,Dongqing Lv,Yiping Zhang,Qitao Yu,Lin Wu,Li Liu,Xiang Wang,Z. Ma,Ying Cheng,Hongrui Niu,Dong Wang,Ji-Feng Feng,Cheng Huang,Chunling Liu,Hui Zhao,Jingzhang Li,Xiao-Dong Zhang,Yong Jiang

Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.

2020

9602Background: Alflutinib (AST2818) is a third generation EGFR-TKI. This phase IIb, multicenter, single arm study (ALSC003, NCT03452592) aimed to assess the efficacyand safety of Alflutinib in pat...

Keywords:

Oncology
Single Arm Study
T790M
Internal medicine
Mutation
Pathology
in patient
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations